KLRK1 and ovarian cancer: Previous reports have showed that the efficacy of NKG2D-based CAR-T cell therapy against ovarian cancer and leukemia was enhanced by upregulating the expression of NKG2DL in target cells with HDAC inhibitor VPA (15, 16).